BTIG lowered the firm’s price target on Jasper Therapeutics (JSPR) to $20 from $64 and keeps a Buy rating on the shares. The Phase 1b/2a BEACON trial update evaluating briquilimab in chronic spontaneous urticaria included a faulty drug lot that impacted efficacy, the analyst tells investors in a research note. The firm says that while the specific issue is yet to be determined, Jasper paused the asthma trial, with the Phase 2b study start in CSU now expected in mid 2026. Despite the pushed out timelines and the asthma catalyst taken off the table, BTIG continues to see briquilmab as a safe and active drug with “compelling” efficacy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Jasper Therapeutics downgraded to Market Perform at William Blair
- Buy Rating Affirmed for Jasper Therapeutics Amid Promising Efficacy and Resolved Trial Setbacks
- Jasper Therapeutics price target lowered to $20 from $40 at H.C. Wainwright
- Jasper Therapeutics Reports Promising Briquilimab Study Results
- Jasper Therapeutics to stop ETESIAN study due to drug product lot issue